Perrone Anna Myriam, Dondi Giulia, Coe Manuela, Ferioli Martina, Telo Silvi, Galuppi Andrea, Crescenzo Eugenia De, Tesei Marco, Castellucci Paolo, Nanni Cristina, Fanti Stefano, Morganti Alessio G, De Iaco Pierandrea
Gynecologic Oncology Unit, Sant'Orsola-Malpighi Hospital, 40138 Bologna, Italy.
Centro di Studio e Ricerca delle Neoplasie Ginecologiche (CSR) University of Bologna, 40138 Bologna, Italy.
Cancers (Basel). 2020 Mar 12;12(3):659. doi: 10.3390/cancers12030659.
Tumor response in locally advanced cervical cancer (LACC) is generally evaluated with MRI and PET, but this strategy is not supported by the literature. Therefore, we compared the diagnostic performance of these two techniques in the response evaluation to concurrent chemoradiotherapy (CCRT) in LACC. Patients with cervical cancer (CC) stage T2b treated with CCRT and submitted to MRI and PET/CT before and after treatment were enrolled in the study. All clinical, pathological, therapeutic, radiologic and follow-up data were collected and examined. The radiological response was analyzed and compared to the follow-up data. Data of 40 patients with LACC were analyzed. Agreement between MRI and PET/CT in the evaluation response to therapy was observed in 31/40 (77.5%) of cases. The agreement between MRI, PET/CT and follow-up data showed a Cohen kappa coefficient of 0.59 (95% CI = 0.267-0.913) and of 0.84 (95% CI = 0.636-1.00), respectively. Considering the evaluation of primary tumor response, PET/CT was correct in 97.5% of cases, and MRI in 92.5% of cases; no false negative cases were observed. These results suggest the use of PET/CT as a unique diagnostic imaging tool after CCRT, to correctly assess residual and progression disease.
局部晚期宫颈癌(LACC)的肿瘤反应通常采用MRI和PET进行评估,但该策略并未得到文献支持。因此,我们比较了这两种技术在LACC同步放化疗(CCRT)反应评估中的诊断性能。本研究纳入了接受CCRT治疗的T2b期宫颈癌(CC)患者,这些患者在治疗前后均接受了MRI和PET/CT检查。收集并检查了所有临床、病理、治疗、放射学和随访数据。分析放射学反应并与随访数据进行比较。对40例LACC患者的数据进行了分析。在31/40(77.5%)的病例中观察到MRI和PET/CT在治疗反应评估方面的一致性。MRI、PET/CT与随访数据之间的一致性分别显示Cohen卡方系数为0.59(95%CI = 0.267 - 0.913)和0.84(95%CI = 0.636 - 1.00)。考虑到对原发肿瘤反应的评估,PET/CT在97.5%的病例中判断正确,MRI在92.5%的病例中判断正确;未观察到假阴性病例。这些结果表明,在CCRT后使用PET/CT作为唯一的诊断成像工具,以正确评估残留和进展性疾病。